Biosimilars

(Image: Getty/LightFieldStudios)

Amgen joins neuroscience exodus

By Ben Hargreaves

In third quarter financials, Amgen announces that it will end its R&D efforts in neuroscience to focus on diseases with a ‘large public health impact.

(Image: Getty/Golubovy)

Top five stories from September

By Ben Hargreaves

The news most interesting to our readers were those featuring collaborations, whether in the production of an Ebola vaccine, biosimilars entering new markets or creating new manufacturing modalities.

Follow us

Products

View more

Webinars